Small US firm VistaGen Therapeutics Inc. is hoping that fresh impetus in the depression market will help propel its candidates towards the market, despite pipeline setbacks.
After around 30 years on pause, the pipeline for depression treatments started to flow again in 2019, with the arrival...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

